Business Context and Reporting Period
Company: Modular Medical, Inc. (MODD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended June 30, 2024 (Fiscal Q1 2025)
Business Overview: A pre-revenue medical device company developing the MODD1, an innovative two-part patch insulin pump. The company submitted a 510(k) premarket notification to the FDA in January 2024 and responded to FDA comments in August 2024.
Key Financial Metrics
| Metric | Q1 2025 (Ended June 30, 2024) | Q1 2024 (Ended June 30, 2023) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,137,000) | $(3,737,000) |
| Net Loss Per Share (Basic & Diluted) | $(0.12) | $(0.22) |
| Operating Expenses | $4,220,000 | $3,751,000 |
| Cash and Cash Equivalents | $5,052,000 | $9,952,000 |
| Net Cash Used in Operating Activities | $(3,548,000) | $(3,207,000) |
| Net Cash Used in Investing Activities | $(842,000) | $(373,000) |
| Net Cash Provided by Financing Activities | $210,000 | $9,733,000 |
| Total Assets | $10,072,000 | $13,807,000 |
| Total Liabilities | $2,056,000 | $2,272,000 |
| Stockholders' Equity | $8,016,000 | $11,535,000 |
Material Changes vs. Prior Period
- Operating Expenses: Increased by $469,000 (12.5%) to $4.22 million. Research and Development (R&D) expenses rose by $437,000 (15.8%) due to higher employee-related costs, consulting fees, and travel, partially offset by lower material costs. General and Administrative (G&A) expenses increased by $32,000 (3.3%) primarily due to legal and professional services.
- Cash Position: Cash and cash equivalents decreased by $4.18 million to $5.05 million, driven by a net cash burn of $3.55 million from operations and $0.84 million from capital expenditures.
- Financing Activity: Unlike the prior year, which saw $9.73 million in proceeds from a public offering, the current quarter generated only $210,000 from warrant exercises. No new equity was issued under the ATM program during this specific quarter.
- Share Count: Outstanding shares increased slightly from 32,464,000 to 32,561,000 due to warrant exercises and stock-based compensation issuances.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The company has expressed substantial doubt about its ability to continue as a going concern for one year from the filing date. Continued operations depend on raising additional capital through equity or debt financing.
- Outlook: Management expects R&D and G&A expenses to remain consistent and then increase in the second half of fiscal 2025. The company anticipates resuming sales under its "at-the-market" (ATM) offering program subject to market conditions.
- Risks: Primary risks include the inability to secure additional capital, which could force curtailment of R&D and cost-cutting measures. The company remains pre-revenue and faces regulatory uncertainty regarding FDA clearance for the MODD1.
- Commitments: Outstanding purchase orders for machinery and equipment total approximately $768,000. A device integration agreement carries a remaining obligation of approximately $400,000 over three years.
- Subsequent Events: On August 2, 2024, 242,307 stock options were cancelled as performance requirements for a milestone bonus program were not achieved.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $5.05 million cash balance against the current burn rate of ~$3.5 million per quarter to assess the timeline for potential dilution or operational curtailment.
- FDA Status: Confirm the current status of the FDA review following the August 2024 response to comments on the MODD1 510(k) submission.
- Capital Raising: Monitor for announcements regarding new equity offerings or debt financing, given the explicit "going concern" warning.
- Expense Trajectory: Track the second half of fiscal 2025 expenses to confirm if the anticipated increase in R&D and G&A aligns with cash availability.
- Stock-Based Compensation: Review the impact of the cancelled options (242,307 shares) on future compensation expense and potential re-grants.